Sports injuries and recovery times could see significant changes with the introduction of an innovative clinical trial led by the University of Cincinnati. Investigating the postoperative effects of tranexamic acid (TXA), the study aims to improve outcomes for young athletes undergoing anterior cruciate ligament (ACL) reconstruction—a frequent consequence of sports mishaps. With a 200,000 annual count of ACL surgeries in the U.S., this has the potential to impact a vast number of patients.
According to an article by the University of Cincinnati, TXA, traditionally administered via IV during surgeries to curb blood loss, will now be tested orally for an extended period post-ACL surgery. While the drug is not unfamiliar in medical contexts, its persevering application could mean faster and more efficient rehab for patients. Given intravenously during surgery, the clinical trial's new approach will observe the effects when prescribed for an additional seven days after the patient's operation.
The principal investigator, Dr. David Bernholt, an associate professor in the Department of Orthopaedic Surgery at UC, will spearhead this multicenter trial. Supported by universities and healthcare institutions across the nation, the study looks to enroll individuals aged between 14 and 22. "This could be a game changer," Bernholt told the University of Cincinnati. "Anything we can do to reduce pain, decrease swelling and promote earlier movement in patients is critical."
Eligibility for the trial encompasses a broad spectrum from high school and college athletes to those suffering from ACL injuries due to trauma. The study's design pits half of the participants receiving the extended TXA regimen against the other half on a placebo. In a recently awarded Sandy Kirkley Clinical Outcomes Research Grant, valued at $25,000 and presented annually to one physician in the U.S., from the American Orthopaedic Society for Sports Medicine (AOSSM), Bernholt received support for his pioneering work in the field.
Details of the trial, including the partnership with other leading institutions like the University of Pittsburgh, Duke University, and Washington University in St. Louis, signify a collaborative effort to enhance recovery protocols for one of the most common sports-related injuries. Patients keen on joining the trial should discuss with their orthopaedic surgeons. As the research unfolds, the extended use of TXA could indeed mark a fundamental shift in ACL surgery recovery.
